efgartigimod

ASH: With immune thrombocytopenia win, argenx proves efgartigimod's no one-trick pony in autoimmune disease
ASH: With immune thrombocytopenia win, argenx proves efgartigimod's no one-trick pony in autoimmune disease
Fierce Pharma
ASH 2022
ITP
efgartigimod
Argenx
Flag link:
Argenx Scores Priority Review for Generalized Myasthenia Gravis Therapeutic
Argenx Scores Priority Review for Generalized Myasthenia Gravis Therapeutic
BioSpace
Argenx
FDA
priority reviews
myasthenia gravis
efgartigimod
Flag link:
Seeking sibling for Vyvgart, argenx files for FDA approval of subcutaneous efgartigimod
Seeking sibling for Vyvgart, argenx files for FDA approval of subcutaneous efgartigimod
Fierce Pharma
Argenx
Vyvgart
myasthenia gravis
efgartigimod
FDA
Flag link:
Data and regulatory roundup: Pfizer’s feat, an ADHD miss, Eli Lilly’s CRL & more
Data and regulatory roundup: Pfizer’s feat, an ADHD miss, Eli Lilly’s CRL & more
MedCity News
FDA
Pfizer
etrasimod
Argenxy
efgartigimod
Aligos Therapeutics
Vallon Pharmaceuticals
Adderall
ORIC Pharmaceuticals
ORIC-101
Neurana Pharmaceuticals
tolperisone
Eli Lilly
sintilimab
Flag link:
Argenx takes a step towards convenience
Argenx takes a step towards convenience
EP Vantage
Argenx
efgartigimod
Vyvgart
myasthenia gravis
Flag link:
Go or no go? Argenx's December showdown
Go or no go? Argenx's December showdown
EP Vantage
FDA
Argenx
efgartigimod
myasthenia gravis
Calliditas
Nefcon
Merck
Keytruda
Flag link:
From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this year
From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this year
Fierce Pharma
FDA
Pfizer
Argenx
UCB Pharma
Roche
efgartigimod
bimekizumab
faricimab
abrocitinib
Flag link:
Aducanumab tops 2021’s biggest potential launches
Aducanumab tops 2021’s biggest potential launches
EP Vantage
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
Flag link:
Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M
Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M
Fierce Biotech
Argenx
Bayer
FDA
priority reviews
efgartigimod
ITP
Flag link:
Biotech Argenx's autoimmune phase 3 hits goals, teeing up FDA filing
Biotech Argenx's autoimmune phase 3 hits goals, teeing up FDA filing
Fierce Biotech
Argenx
efgartigimod
myasthenia gravis
Flag link:
Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
EP Vantage
Wave Life Sciences
WVE-120101
Huntington's disease
Argenx
efgartigimod
autoimmune disease
Flag link: